[11C] Methionine and [18F] Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 84, Issue 3, 2007, Pages 305-314

  Pötzi, Christian ^a   Becherer, Alexander ^a   Marosi, Christine ^a   Karanikas, Georgios ^a   Szabo, Monika ^a   Dudczak, Robert ^a   Kletter, Kurt ^a   Asenbaum, Susanne ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

FDG; Glioblastoma multiforme; Methionine; PET; Tumor recurrence

Indexed keywords

CARBON; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; METHIONINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BRAIN TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; KAPLAN MEIER METHOD; MALE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR RECURRENCE;

BRAIN NEOPLASMS; CARBON RADIOISOTOPES; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 35448942790     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9375-6     Document Type: Article

References (39)

1. Goldman S, Levivier M, Pirotte B et al (1996) Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 78:1098–1106 DOI: 10.1002/(SICI)1097-0142(19960901)78:5<1098::AID-CNCR21>3.0.CO;2-X
2. Di Chiro G, DeLaPaz RL, Brooks RA et al (1982) Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32:1323–1329
3. Langleben DD, Segall GM (2000) PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 41:1861–1867
4. Chao ST, Suh JH, Raja S et al (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96:191–197 DOI: 10.1002/ijc.1016
5. Benard F, Romsa J, Hustinx R (2003) Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 33:148–162 DOI: 10.1053/snuc.2003.127304
6. Ogawa T, Shishido F, Kanno I et al (1993) Cerebral glioma: evaluation with methionine PET. Radiology 186:45–53
7. Jager PL, Vaalburg W, Pruim J et al (2001) Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42:432–445
8. Kuwert T, Woesler B, Morgenroth C et al (1998) Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 39:23–27
9. 123I]iodo-alpha-methyl-l-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. Eur J Nucl Med 28:855–861 DOI: 10.1007/s002590100553
10. 11C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur J Nucl Med Mol Imaging 29:632–640 DOI: 10.1007/s00259-002-0762-0
11. Riemann B, Papke K, Hoess N et al (2002) Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-l-alpha-methyltyrosine SPECT. Radiology 225:567–574 DOI: 10.1148/radiol.2252011431
12. De Witte O, Goldberg I, Wikler D et al (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95:746–750
13. Levivier M, Wikler D Jr, Massager N et al (2002) The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg 97:542–550
14. Pirotte B, Goldman S, Salzberg S et al (2003) Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg 38:146–155 DOI: 10.1159/000068820
15. Young R (1998) The role of the gamma knife in the treatment of malignant primary and metastatic brain tumors. CA Cancer J Clin 48:177–188
16. Nishimura R, Takahashi M, Morishita S et al (1992) MR Gd-DTPA enhancement of radiation brain injury. Radiat Med 10:109–116
17. Ishiwata K, Ido T, Vaalburg W (1988) Increased amounts of D-enantiomer dependent on alkaline concentration in the synthesis of l-[methyl-11C]methionine. Int J Rad Appl Instrum [A] 39:311–314 DOI: 10.1016/0883-2889(88)90021-4
18. Chung JK, Kim YK, Kim SK et al (2002) Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29:176–182 DOI: 10.1007/s00259-001-0690-4
19. Herholz K, Holzer T, Bauer B et al (1998) 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50:1316–1322
20. Kracht LW, Miletic H, Busch S et al (2004) Delineation of brain tumor extent with [11C]l-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 10:7163–7170 DOI: 10.1158/1078-0432.CCR-04-0262
21. 11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 32:197–202 DOI: 10.3109/02841859109177547
22. Van Laere K, Ceyssens S, Van Calenbergh F et al (2005) Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 32:39–51 DOI: 10.1007/s00259-004-1564-3
23. Kim S, Chung JK, Im SH et al (2005) 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 32:52–59 DOI: 10.1007/s00259-004-1598-6
24. Nariai T, Tanaka Y, Wakimoto H et al (2005) Usefulness of l-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498–507
25. Spence AM, Mankoff DA, Muzi M (2003) Positron emission tomography imaging of brain tumors. Neuroimag Clin N AM 13:717–739 DOI: 10.1016/S1052-5149(03)00097-2
26. Ogawa T, Inugami A, Hatazawa J et al (1996) Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and l-methyl-11C-methionine. AJNR Am J Neuroradiol 17:345–353
27. Lichy MP, Henze M, Plathow C et al (2004) Metabolic imaging to follow stereotactic radiation of gliomas – the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT. Rofo 176:1114–1121
28. Woesler B, Kuwert T, Morgenroth C et al (1997) Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose. Eur J Nucl Med 24:428–434
29. Rozental JM, Cohen JD, Mehta MP et al (1993) Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neurooncol 15:57–66 DOI: 10.1007/BF01050264
30. Herholz K, Kracht LW, Heiss WD (2003) Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 13:269–271 DOI: 10.1177/1051228403013003012
31. Padma MV, Said S, Jacobs M et al (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227–237 DOI: 10.1023/A:1025665820001
32. Roelcke U, Blasberg RG, von Ammon K et al (1998) Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 39:879–884
33. De Witte O, Lefranc F, Levivier M et al (2000) FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 49:157–163 DOI: 10.1023/A:1026518002800
34. Barker FG 2nd, Chang SM, Valk PE et al (1997) 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79:115–126 DOI: 10.1002/(SICI)1097-0142(19970101)79:1<115::AID-CNCR17>3.0.CO;2-7
35. Hammoud MA, Sawaya R, Shi W et al (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65–73 DOI: 10.1007/BF00146086
36. Tsuyuguchi N, Takami T, Sunada I et al (2004) Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery—in malignant glioma. Ann Nucl Med 18:291–296 DOI: 10.1007/BF02984466
37. Lacroix M, Abi-Said D, Fourney DR F et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198
38. Chow KL, Gobin YP, Cloughesy T et al (2000) Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR 21:471–478
39. Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371–379 DOI: 10.1016/S0090-3019(99)00103-2